Effectiveness of combined botulinum toxin and fissurectomy on chronic anal fissures - a systematic review.

IF 1.5 4区 医学 Q3 SURGERY
Rakesh Quinn, Giuleta Jamsari, Gary Kk Low, Sinan Albayati
{"title":"Effectiveness of combined botulinum toxin and fissurectomy on chronic anal fissures - a systematic review.","authors":"Rakesh Quinn, Giuleta Jamsari, Gary Kk Low, Sinan Albayati","doi":"10.1111/ans.19248","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anal fissures are a debilitating benign condition, thought to be due to the hypertonicity of the internal anal sphincter resulting in localized ischaemia inhibiting healing. There are several surgical and non-surgical treatment options for chronic anal fissures. Clinical practice surveys report a trend toward sphincter-sparing options, reserving the more successful treatment of lateral sphincterotomy, with an incontinence rate up to 10%, for refractory fissures.</p><p><strong>Methods: </strong>A search of MEDLINE, Cochrane Database of Systematic Reviews and EMBASE for studies assessing sphincter-sparing treatment with botulinum toxin and fissurectomy was performed following PRISMA guidelines. Outcomes assessed included healing rate, persistence, recurrence, re-intervention and incontinence rates.</p><p><strong>Results: </strong>Fifteen non-randomized studies assessed 978 patients managed with botulinum toxin and fissurectomy. The mean age was 40.8 years with a female predominance of 58.9%. Healing rate was reported on 14 of the 15 studies, with a healing rate of 81% (95% CI:0.67, 0.90). Persistence rate was reported as 15% (95% CI:0.07, 0.28) and a recurrence rate of 6% (95% CI: 0.01, 0.19). Re-intervention was required in 8% of patients with 55.1% requiring a repeat dose of botulinum toxin with or without fissurectomy. Incontinence appears to be transient with studies reporting a rate of 1% with median long-term follow up 23 months (range: 5-60 months).</p><p><strong>Conclusion: </strong>Combination fissurectomy and botulinum toxin is a safe and viable sphincter sparing treatment option, with moderate success rate and negligible complications. Randomized controlled trials are required to further strengthen the evidence for its use in chronic anal fissures.</p>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ANZ Journal of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ans.19248","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Anal fissures are a debilitating benign condition, thought to be due to the hypertonicity of the internal anal sphincter resulting in localized ischaemia inhibiting healing. There are several surgical and non-surgical treatment options for chronic anal fissures. Clinical practice surveys report a trend toward sphincter-sparing options, reserving the more successful treatment of lateral sphincterotomy, with an incontinence rate up to 10%, for refractory fissures.

Methods: A search of MEDLINE, Cochrane Database of Systematic Reviews and EMBASE for studies assessing sphincter-sparing treatment with botulinum toxin and fissurectomy was performed following PRISMA guidelines. Outcomes assessed included healing rate, persistence, recurrence, re-intervention and incontinence rates.

Results: Fifteen non-randomized studies assessed 978 patients managed with botulinum toxin and fissurectomy. The mean age was 40.8 years with a female predominance of 58.9%. Healing rate was reported on 14 of the 15 studies, with a healing rate of 81% (95% CI:0.67, 0.90). Persistence rate was reported as 15% (95% CI:0.07, 0.28) and a recurrence rate of 6% (95% CI: 0.01, 0.19). Re-intervention was required in 8% of patients with 55.1% requiring a repeat dose of botulinum toxin with or without fissurectomy. Incontinence appears to be transient with studies reporting a rate of 1% with median long-term follow up 23 months (range: 5-60 months).

Conclusion: Combination fissurectomy and botulinum toxin is a safe and viable sphincter sparing treatment option, with moderate success rate and negligible complications. Randomized controlled trials are required to further strengthen the evidence for its use in chronic anal fissures.

肉毒杆菌毒素和肛裂切除术联合治疗慢性肛裂的效果--系统性综述。
背景:肛裂是一种使人衰弱的良性疾病,被认为是由于肛门内括约肌张力过高导致局部缺血而抑制愈合。慢性肛裂有多种手术和非手术治疗方法。临床实践调查报告显示,目前的趋势是选择保留括约肌的治疗方法,而对于难治性肛裂,则保留更为成功的侧括约肌切开术,其失禁率高达 10%:方法:按照 PRISMA 指南,在 MEDLINE、Cochrane 系统综述数据库和 EMBASE 中搜索评估肉毒杆菌毒素括约肌保留治疗和肛裂切除术的研究。评估结果包括痊愈率、持续率、复发率、再次干预率和失禁率:15项非随机研究评估了978名接受肉毒杆菌毒素和肛裂切除术治疗的患者。平均年龄为 40.8 岁,女性占 58.9%。15 项研究中有 14 项报告了治愈率,治愈率为 81% (95% CI:0.67, 0.90)。持续率为 15%(95% CI:0.07, 0.28),复发率为 6%(95% CI:0.01, 0.19)。8%的患者需要再次干预,其中55.1%的患者需要再次注射肉毒杆菌毒素,同时进行或不进行裂隙切除术。尿失禁似乎是一过性的,有研究报告称其发生率为1%,长期随访的中位数为23个月(范围:5-60个月):结论:裂隙切除术和肉毒杆菌毒素联合疗法是一种安全可行的括约肌疏通治疗方案,成功率中等,并发症可忽略不计。需要进行随机对照试验,以进一步加强该疗法用于慢性肛裂的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ANZ Journal of Surgery
ANZ Journal of Surgery 医学-外科
CiteScore
2.50
自引率
11.80%
发文量
720
审稿时长
2 months
期刊介绍: ANZ Journal of Surgery is published by Wiley on behalf of the Royal Australasian College of Surgeons to provide a medium for the publication of peer-reviewed original contributions related to clinical practice and/or research in all fields of surgery and related disciplines. It also provides a programme of continuing education for surgeons. All articles are peer-reviewed by at least two researchers expert in the field of the submitted paper.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信